-
Why early detection matters ? HCC is the most common primary liver cancer and one of the deadliest: in 2020, an estimated 905,700 people were diagnosed and 830,200 died worldwide.¹ Survival changes dramatically with stage, detecting HCC early can more than triple 5-year survival compared with late discovery.² The current standard and its blind spots […]
(1493)(0)
Published: Sep 23, 2025A review paper was published in the peer-reviewed journal Diagnostics, titled “Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)”. The paper analyzes the publicly available data on the LC-SPIK biomarker and its performance in detecting early stage liver cancer, […]
(42173)(0)
Published: Apr 12, 2024A recent study has been published by investigators at the University of Turin in the peer-reviewed journal Current Oncology. This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 […]
(88615)(0)
Published: Aug 11, 2022ImCare Biotech has been awarded a Phase IIB Bridge Award by the National Cancer Institute (NCI/NIH). This up to $4M over three-year award will be used to help ImCare Biotech pursue commercialization activities and support a pivotal clinical study for FDA clearance of Seravue®, a diagnostic testing product for Hepatocellular Carcinoma (HCC). This follows the […]
(98335)(0)
Published: Oct 29, 2021